Genome editing: the road of CRISPR/Cas9 from bench to clinic
A Eid, MM Mahfouz - Experimental & Molecular Medicine, 2016 - nature.com
Molecular scissors engineered for site-specific modification of the genome hold great
promise for effective functional analyses of genes, genomes and epigenomes and could …
promise for effective functional analyses of genes, genomes and epigenomes and could …
Advances in therapeutic application of CRISPR-Cas9
J Sun, J Wang, D Zheng, X Hu - Briefings in Functional …, 2020 - academic.oup.com
Clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9
(Cas9) is one of the most versatile and efficient gene editing technologies, which is derived …
(Cas9) is one of the most versatile and efficient gene editing technologies, which is derived …
Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies
M Mehravar, E Roshandel, M Salimi, R Chegeni… - Immunology …, 2020 - Elsevier
The ability to change the genetic information of immune cells is a powerful tool for basic and
clinical settings. CRISPR/Cas9 gene editing technology by providing an efficient approach …
clinical settings. CRISPR/Cas9 gene editing technology by providing an efficient approach …
CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia
AM Alayoubi, ZY Khawaji, MA Mohammed… - Annals of …, 2024 - Springer
Gene therapy represents a significant potential to revolutionize the field of hematology with
applications in correcting genetic mutations, generating cell lines and animal models, and …
applications in correcting genetic mutations, generating cell lines and animal models, and …
Development and application of CRISPR/Cas9 technologies in genomic editing
C Zhang, R Quan, J Wang - Human molecular genetics, 2018 - academic.oup.com
Genomic editing to correct disease-causing mutations is a promising approach for the
treatment of human diseases. As a simple and programmable nuclease-based genomic …
treatment of human diseases. As a simple and programmable nuclease-based genomic …
A review of CRISPR-based genome editing: survival, evolution and challenges
Precise nucleic acid editing technologies have facilitated the research of cellular function
and the development of novel therapeutics, especially the current programmable nucleases …
and the development of novel therapeutics, especially the current programmable nucleases …
[HTML][HTML] CRISPR–Cas9 gene editing induced complex on-target outcomes in human cells
W Wen, XB Zhang - Experimental Hematology, 2022 - Elsevier
Highlights•Unwanted on-target mutation occurs after CRISPR–Cas9 cleavage.•Assessment
of comprehensive on-target outcomes is necessary.•Clinical genomic engineering requires …
of comprehensive on-target outcomes is necessary.•Clinical genomic engineering requires …
CRISPR-Cas9 technology for the creation of biological avatars capable of modeling and treating pathologies: From discovery to the latest improvements
This is a spectacular moment for genetics to evolve in genome editing, which encompasses
the precise alteration of the cellular DNA sequences within various species. One of the most …
the precise alteration of the cellular DNA sequences within various species. One of the most …
CRISPR/Cas: from tumor gene editing to T cell-based immunotherapy of cancer
The clustered regularly interspaced short palindromic repeats system has demonstrated
considerable advantages over other nuclease-based genome editing tools due to its high …
considerable advantages over other nuclease-based genome editing tools due to its high …
CRISPR-Cas9 technology as a tool to target gene drivers in cancer: proof of concept and new opportunities to treat chronic myeloid leukemia
E Vuelta, JL Ordoñez, V Alonso-Pérez… - The CRISPR …, 2021 - liebertpub.com
Chronic myeloid leukemia (CML) is a hematopoietic malignancy produced by a unique
oncogenic event involving the constitutively active tyrosine-kinase (TK) BCR/ABL1. TK …
oncogenic event involving the constitutively active tyrosine-kinase (TK) BCR/ABL1. TK …